Related Articles
|
Forget 2016! Why AstraZeneca plc & Royal Mail PLC Are Exceptional Long-Term …
The Motley Fool UK Growth hunters would have been well advised to steer well clear of pharmaceuticals giant AstraZeneca (LSE: AZN) in recent years. A steady stream of patent losses across critical labels, such as its Nexium stomach treatment, has created prolonged havoc … |
More: continued here
